Medtronic plc

Medtronic is currently trading at an attractive valuation, presenting a compelling opportunity given its superior profit margins and dominant position in the medical technology sector. With an average analyst price target of $97.84 and historical 52-week gains averaging 19.2%, significant upside remains.

Multiple analysts have been cutting their price targets sharply, with TD Cowen slashing its target from $119 to $100, and UBS issuing a low target of $76. Earnings estimate revisions have also turned negative, with the consensus EPS declining 2.2% over the last month, suggesting deteriorating near-term fundamentals.

Medtronic is forecast to deliver meaningful earnings per share growth, rising to $5.94 for the year with analysts estimating consecutive quarterly increases. Argus Research maintains the highest price target at $115, reflecting confidence in the company's ability to sustain and accelerate its earnings trajectory.

Growing skepticism surrounds Medtronic's earnings outlook, with analysts broadly revising EPS estimates downward. The strong consensus in lowering projections has resulted in a Zacks Rank of 4 (Sell), cautioning investors against relying on the otherwise buy-leaning average brokerage recommendation.

With 29 analysts contributing to a mean consensus of Outperform and firms like BTIG Research, Citigroup, Morgan Stanley, and Leerink Partners maintaining Buy or Outperform ratings with targets well above the current price, the majority view supports a meaningful recovery in MDT's stock price.

Despite the headline Outperform consensus, key firms such as Baird, UBS, Truist Securities, Stifel, and Needham maintain Neutral or Hold ratings. TD Cowen's steep price target cut from $119 to $100 and Baird's maintained Neutral rating signal that conviction among analysts remains far from uniform.